Eprex is a medicine containing the active ingredient(s) epoetin alfa. On this page you will find out more about Eprex, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: epoetin alfa
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Eprex 40 000 units/mL injection solution, 1 mL syringe
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. Eprex is also indicated for the treatment of anaemia and reduction of transfusion in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy. Eprex is also indicated in adult patients with mild- to-moderate anaemia (haemoglobin > 100 to <= 130 g/L) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 mL) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery. EPREX is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to pre-deposit their complete peri-operative blood needs.
Table of characteristics
|Visual appearance||Colourless solution.|
|Dosage Form||Injection, solution|
|Route of administration||Intravenous|
1 x 1.0mL: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Protect from Light,Do not Shake|
|Life time||18 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 November 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Eprex | myVMC
Eprex is used to treat anaemia related to chronic renal failure. It contains epoetin alfa, which stimulates red blood cell production.
Read more on myVMC – Virtual Medical Centre website
Eprex Solution for injection - myDr.com.au
Eprex Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 1 results
Erythropoietin or darbepoetin for patients with cancer | Cochrane
Researchers in The Cochrane Collaboration conducted a review of the effect of epoetin and darbepoetin for people with cancer. After searching for all relevant studies, they found 91 studies with up to 20,102 people. Their findings are summarized below:
Read more on Cochrane (Australasian Centre) website